DiaMedica Therapeutics (DMAC) Competitors $3.65 +0.08 (+2.24%) Closing price 07/3/2025 03:41 PM EasternExtended Trading$3.72 +0.07 (+2.03%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. NUVB, DAWN, GHRS, STOK, SANA, MRVI, URGN, AUTL, CDXC, and CDTXShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Stoke Therapeutics (STOK), Sana Biotechnology (SANA), Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors Nuvation Bio Day One Biopharmaceuticals GH Research Stoke Therapeutics Sana Biotechnology Maravai LifeSciences Urogen Pharma Autolus Therapeutics ChromaDex Cidara Therapeutics Nuvation Bio (NYSE:NUVB) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings. Is NUVB or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -5,534.21%. Nuvation Bio's return on equity of -44.14% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% DiaMedica Therapeutics N/A -61.35%-55.53% Do analysts recommend NUVB or DMAC? Nuvation Bio currently has a consensus target price of $7.17, indicating a potential upside of 243.73%. DiaMedica Therapeutics has a consensus target price of $8.00, indicating a potential upside of 119.18%. Given Nuvation Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Nuvation Bio is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to NUVB or DMAC? In the previous week, Nuvation Bio had 2 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Nuvation Bio and 1 mentions for DiaMedica Therapeutics. Nuvation Bio's average media sentiment score of 0.25 beat DiaMedica Therapeutics' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in NUVB or DMAC? 61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, NUVB or DMAC? Nuvation Bio has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Which has stronger earnings & valuation, NUVB or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Nuvation Bio. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M90.15-$567.94M-$2.35-0.89DiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-5.70 SummaryNuvation Bio beats DiaMedica Therapeutics on 13 of the 16 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.24M$2.89B$5.53B$9.04BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-5.7021.7127.6320.25Price / SalesN/A281.07417.36118.60Price / CashN/A42.7336.8958.07Price / Book3.847.518.035.67Net Income-$24.44M-$55.14M$3.18B$249.21M7 Day Performance-4.95%4.61%2.91%3.28%1 Month Performance-10.76%4.72%3.72%5.55%1 Year Performance25.86%5.92%35.14%21.08% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics0.9035 of 5 stars$3.65+2.2%$8.00+119.2%+26.3%$161.24MN/A-5.7020NUVBNuvation Bio3.4495 of 5 stars$1.96+1.3%$7.17+266.6%-28.7%$656.71M$7.87M0.0060High Trading VolumeDAWNDay One Biopharmaceuticals1.7341 of 5 stars$6.50+0.5%$30.57+370.3%-49.6%$655.82M$131.16M0.0060Upcoming EarningsGHRSGH Research2.0695 of 5 stars$12.19-2.0%$32.00+162.5%+23.7%$647.23MN/A0.0010Analyst UpgradeSTOKStoke Therapeutics4.0338 of 5 stars$11.35-2.4%$23.20+104.4%-9.4%$634.96M$36.56M14.72100Analyst ForecastSANASana Biotechnology2.7825 of 5 stars$2.73-2.8%$8.60+215.0%-38.8%$633.59MN/A0.00380Analyst ForecastGap UpMRVIMaravai LifeSciences3.4856 of 5 stars$2.41-2.4%$6.64+175.5%-60.4%$629.01M$259.18M0.00610URGNUrogen Pharma4.4706 of 5 stars$13.70+1.6%$32.86+139.8%-10.1%$621.99M$90.40M0.00200AUTLAutolus Therapeutics2.5559 of 5 stars$2.28-1.3%$9.32+308.8%-32.1%$614.79M$10.12M0.00330CDXCChromaDex3.222 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120CDTXCidara Therapeutics4.2435 of 5 stars$48.71-1.5%$57.14+17.3%+293.1%$603.74M$1.27M0.0090High Trading Volume Related Companies and Tools Related Companies Nuvation Bio Alternatives Day One Biopharmaceuticals Alternatives GH Research Alternatives Stoke Therapeutics Alternatives Sana Biotechnology Alternatives Maravai LifeSciences Alternatives Urogen Pharma Alternatives Autolus Therapeutics Alternatives ChromaDex Alternatives Cidara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
